{"id":"ics-laba-medication","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"5-10","effect":"Oral candidiasis"},{"rate":"5-10","effect":"Hoarseness"},{"rate":"1-5","effect":"Nervousness/anxiety"}]},"_chembl":{"chemblId":"CHEMBL556193","moleculeType":"Small molecule","molecularWeight":"334.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The inhaled corticosteroid (ICS) component suppresses inflammatory pathways in the airways, reducing mucus production and airway edema. The long-acting beta-2 agonist (LABA) binds to beta-2 adrenergic receptors on airway smooth muscle, causing sustained bronchodilation over 12-24 hours. Together, they provide both anti-inflammatory and bronchodilatory effects for improved airflow and symptom control.","oneSentence":"ICS/LABA combines an inhaled corticosteroid to reduce airway inflammation with a long-acting beta-2 agonist to relax airway smooth muscle and improve bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:58.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT06419413","phase":"","title":"A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-08","conditions":"Asthma","enrollment":355},{"nctId":"NCT07051707","phase":"NA","title":"Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD","status":"RECRUITING","sponsor":"Nuvaira, Inc.","startDate":"2026-02-15","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07372521","phase":"","title":"Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ioannina","startDate":"2026-01-19","conditions":"Asthma","enrollment":130},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT04481555","phase":"PHASE4","title":"Eosinophil-guided Reduction of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2021-06-28","conditions":"COPD, Inhaled Corticosteroid, Azithromycin","enrollment":444},{"nctId":"NCT07351916","phase":"","title":"Remission in Adults With Mild-to-moderate Asthma in Thailand","status":"NOT_YET_RECRUITING","sponsor":"Thammasat University","startDate":"2026-02-01","conditions":"Asthma, Mild-to-moderate Asthma, Asthma Control Level","enrollment":289},{"nctId":"NCT07272278","phase":"NA","title":"Prospective Clinical Study on the Clinical Efficacy and Prognostic Outcome of ICS/LABA Combined With Liqin Zhike Formula in the Treatment of Cough Variant Asthma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-01","conditions":"Asthma","enrollment":236},{"nctId":"NCT06465485","phase":"PHASE3","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-28","conditions":"Severe Eosinophilic Asthma","enrollment":504},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT06908421","phase":"","title":"Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence","status":"RECRUITING","sponsor":"Chiesi Pharma AB, Nordic","startDate":"2025-09-15","conditions":"Asthma","enrollment":60},{"nctId":"NCT04651777","phase":"PHASE3","title":"Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Grace Parraga","startDate":"2022-08-08","conditions":"Asthma","enrollment":31},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT06721247","phase":"PHASE2, PHASE3","title":"Oral Intake of Mg in Controlled Asthmatic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-11-02","conditions":"Bronchial Asthma","enrollment":166},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT04664491","phase":"NA","title":"Effects of COPD Standardized Management on COPD Exacerbation","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2023-02-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3456},{"nctId":"NCT05009758","phase":"NA","title":"Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2021-09-01","conditions":"Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)","enrollment":30},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT06360393","phase":"","title":"Inhaler Adherence and Inhalation Technique Assessed by a Smart Spacer in Patients with Severe Asthma on Biologics","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-05-01","conditions":"Asthma","enrollment":110},{"nctId":"NCT06105671","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Formoterol","status":"COMPLETED","sponsor":"Morten Hostrup, PhD","startDate":"2024-01-05","conditions":"Exercise Performance","enrollment":20},{"nctId":"NCT05104892","phase":"PHASE2","title":"Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-12","conditions":"Asthma","enrollment":196},{"nctId":"NCT03654976","phase":"PHASE3","title":"Mite Asthma Pediatric Immunotherapy Trial","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2018-02-22","conditions":"Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite","enrollment":533},{"nctId":"NCT05331755","phase":"","title":"Real Life Experience Survey of Dupilumab in the Netherlands","status":"COMPLETED","sponsor":"Gert-Jan Braunstahl","startDate":"2021-04-01","conditions":"Severe Asthma","enrollment":120},{"nctId":"NCT03489746","phase":"NA","title":"Steroid Withdrawal Intervention in Fife and Tayside","status":"WITHDRAWN","sponsor":"NHS Tayside","startDate":"2018-05-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT05459805","phase":"NA","title":"Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2022-03-01","conditions":"Cough Variant Asthma","enrollment":164},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT04172701","phase":"","title":"A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9284},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT03083067","phase":"NA","title":"Salvational Intervention for Reducing AECOPD Under Severe Air Pollution","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2017-03-20","conditions":"COPD Exacerbation, Air Pollution","enrollment":402},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT04206761","phase":"PHASE3","title":"Investigating the Effects of QVM149 on MRI Ventilation Defects","status":"WITHDRAWN","sponsor":"Dr. Grace Parraga","startDate":"2021-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT04737655","phase":"PHASE4","title":"Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care","status":"UNKNOWN","sponsor":"PARZIBUT Gilles","startDate":"2021-02-15","conditions":"COPD Exacerbation","enrollment":200},{"nctId":"NCT02147015","phase":"NA","title":"Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2014-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":248},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT04520230","phase":"PHASE4","title":"Three Treatment of Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-10-31","conditions":"COPD","enrollment":45},{"nctId":"NCT03550456","phase":"","title":"Diagnostics and Quality of Life With EIA and EILO","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2018-11-01","conditions":"Exercise Induced Asthma, Exercise Induced Pharyngeal Collapse","enrollment":40},{"nctId":"NCT04322422","phase":"NA","title":"Clinical Characteristics and Treatment of Chest Tightness Variant Asthma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-06-01","conditions":"Asthma, Chest Syndrome, Clinical Anxiety","enrollment":300},{"nctId":"NCT02850185","phase":"NA","title":"Adjuvant Therapy for Severe COPD Patients in the Stable Phase by an Oxyhydrogen Generator With Nebulizer","status":"UNKNOWN","sponsor":"Shanghai Asclepius Meditec Inc.","startDate":"2016-07-15","conditions":"COPD","enrollment":170},{"nctId":"NCT04000958","phase":"NA","title":"PIFR-based Inhalation Therapy in Patients Recovering From AECOPD","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-09-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":460},{"nctId":"NCT02546297","phase":"PHASE4","title":"Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-09-15","conditions":"COPD, Bronchiectasis","enrollment":90},{"nctId":"NCT03376295","phase":"","title":"Comparative Effectiveness of COPD Treatments","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3954},{"nctId":"NCT02537691","phase":"PHASE4","title":"Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-28","conditions":"Asthma","enrollment":483},{"nctId":"NCT01967173","phase":"PHASE3","title":"Best African American Response to Asthma Drugs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT03498742","phase":"","title":"Asthmatic Subjects Could Live Without Short Acting beta2 Agonists","status":"COMPLETED","sponsor":"Universidad Nacional de Rosario","startDate":"2017-03-10","conditions":"Asthma Chronic","enrollment":86},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02105974","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1621},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01329029","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1945},{"nctId":"NCT02782312","phase":"PHASE4","title":"Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2011-06","conditions":"Bronchiectasis","enrollment":120},{"nctId":"NCT01213693","phase":"NA","title":"Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2009-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":60},{"nctId":"NCT00784953","phase":"","title":"Real Life Effectiveness in Patients With Not Optimally Controlled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Asthma","enrollment":842},{"nctId":"NCT02556073","phase":"NA","title":"ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-08","conditions":"Asthma","enrollment":112},{"nctId":"NCT01763463","phase":"","title":"WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01681979","phase":"","title":"WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Asthma","enrollment":1},{"nctId":"NCT01404013","phase":"PHASE4","title":"Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2012-02","conditions":"Asthma","enrollment":99},{"nctId":"NCT02094274","phase":"PHASE1","title":"A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2013-11","conditions":"Asthma","enrollment":30},{"nctId":"NCT01908075","phase":"","title":"Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-01","conditions":"Asthma","enrollment":194723},{"nctId":"NCT01697722","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"1991-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT01647646","phase":"PHASE4","title":"Real Life Effectiveness in Patients With Not Optimally Controlled Asthma","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-03","conditions":"Asthma","enrollment":200},{"nctId":"NCT01565031","phase":"","title":"Prediction of Future Risk in Patients With Controlled Asthma","status":"UNKNOWN","sponsor":"Luis Perez de Llano","startDate":"2012-05","conditions":"Asthma","enrollment":338},{"nctId":"NCT00567476","phase":"PHASE4","title":"Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ICS/LABA medication","genericName":"ICS/LABA medication","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ICS/LABA combines an inhaled corticosteroid to reduce airway inflammation with a long-acting beta-2 agonist to relax airway smooth muscle and improve bronchodilation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}